Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · IEX Real-Time Price · USD
4.260
-0.130 (-2.96%)
At close: Jul 19, 2024, 4:00 PM
4.210
-0.050 (-1.17%)
Pre-market: Jul 22, 2024, 8:14 AM EDT

Monte Rosa Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Ending
CurrentDec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Market Capitalization
261283368950--
Market Cap Growth
-8.04%-23.18%-61.22%---
Enterprise Value
10892152604-43-8
PE Ratio
--2.09-3.39-12.84--
PS Ratio
244.83-----
PB Ratio
1.711.581.362.73--
P/FCF Ratio
-5.07-4.51-3.50-13.76--
P/OCF Ratio
-6.04-6.46-3.98-16.00--
EV/Sales Ratio
101.44-----
EV/EBITDA Ratio
-1.57-0.71-1.52-8.401.211.11
EV/EBIT Ratio
-1.49-0.68-1.40-8.161.191.10
EV/FCF Ratio
-2.88-1.47-1.44-8.751.621.12
Debt / Equity Ratio
0.300.260.17---0.06
Debt / EBITDA Ratio
-0.35-0.36-0.47---0.10
Debt / FCF Ratio
-0.65-0.73-0.45---0.10
Quick Ratio
4.805.1010.6220.801.462.15
Current Ratio
4.825.0710.7920.961.492.27
Asset Turnover
0.000000-
Return on Equity (ROE)
-74.10%-65.90%-36.50%-29.20%117.90%-
Return on Assets (ROA)
-49.10%-47.30%-30.80%-22.80%-118.70%-
Return on Capital (ROIC)
-72.84%-63.61%-35.29%-20.97%57.48%70.14%
Earnings Yield
-51.93%-47.83%-29.46%-7.79%--
FCF Yield
-26.77%-22.19%-28.58%-7.27%--
Buyback Yield / Dilution
-21.90%-8.83%-88.91%-1548.09%69.66%-
Total Shareholder Return
-21.90%-8.83%-88.91%-1548.09%69.66%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).